Ra pharmaceuticals, inc. (RARX)
CashFlow / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities
Net loss

-102,688

-82,106

-73,635

-67,484

-64,943

-63,889

-62,660

-59,577

-54,439

-50,186

-43,025

-35,168

-28,864

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,619

2,017

1,888

1,741

1,597

1,589

1,566

1,564

1,524

1,394

1,335

1,349

1,274

0

0

0

Stock-based compensation

14,045

12,290

10,272

8,639

7,695

7,279

7,081

6,501

5,573

4,352

3,005

1,919

1,026

0

0

0

Other, net

-74

0

0

0

-

-

-

-

-

-

-

-

-84

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

6,985

5,118

2,981

2,067

49

1,343

1,870

345

1,023

591

158

-1,253

890

0

0

0

Accounts payable and accrued expenses

7,020

3,041

2,875

2,290

1,126

292

1,415

1,961

2,012

2,074

1,423

1,879

4,018

0

0

0

Operating lease liabilities

-1,007

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-2,389

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-1,862

0

0

0

Other, net

-

-

-

-

19

36

26

-8

19

0

0

0

-

-

-

-

Net cash used in operating activities

-87,361

-70,824

-62,292

-57,451

-54,946

-56,523

-54,908

-50,295

-46,779

-42,152

-37,433

-28,195

-21,843

0

0

0

Purchase of property and equipment

865

748

892

1,200

1,034

937

842

962

1,412

2,001

3,012

5,527

5,105

0

0

0

Net cash used in investing activities

-865

-748

-892

-1,200

-1,034

-937

-842

-962

-1,412

-2,128

-3,136

-5,521

-5,096

0

0

0

Cash flows from financing activities
Proceeds from common stock offering, net of underwriter discounts

-

-

-

-

195,014

0

0

0

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payment of common stock offering costs

540

572

618

451

403

0

0

0

-

-

-

-

-

-

-

-

Payments related to restricted stock units vesting

583

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercises of stock options and ESPP shares

3,989

0

0

0

-

-

-

-

266

0

0

0

-

-

-

-

Net cash provided by financing activities

143,396

283,115

141,730

141,176

195,421

54,428

54,202

55,006

760

0

0

0

-

-

-

-

Net change in cash, cash equivalents and restricted cash

55,170

211,543

78,546

82,525

139,441

-3,032

-1,548

3,749

-47,431

0

0

0

-

-

-

0

Noncash investing and financing activity:
Common stock offering costs incurred but unpaid at period end

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Changes in liabilities and prepaid expenses related to fixed asset additions

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-